Innovative Therapies and Radiosurgery in Brain Metastasis

Despite advances in multimodality management of brain metastases, local progression following stereotactic radiosurgery (SRS) can occur. Often, surgical resection is favored, as it frequently provides immediate symptom relief as well as pathological characterization of any residual tumor. During this course, Dr. Manmeet S. Ahluwalia will discuss and analyze the innovative therapies and radiosurgery available when treating patients with brain metastasis. 

Commercial Supporter

Baptist Health gratefully acknowledges the commercial support provided by Elekta for this activity.

Target Audience

Neurosurgeons, medical physicists, radiation oncologists, neuro-otolaryngologists, nurses and advanced practice registered nurses. 

Learning Objectives

  • Identify the role of genetics in outcomes in brain metastases. 
  • Summarize the role of targeted therapy in brain metastases. 
  • Describe the role of immunotherapy in brain metastases. 
Additional information
Bibliography: 
  • Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., ... & Solomon, B. J. (2020). First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. New England Journal of Medicine, 383(21), 2018-2029.
  • Goldberg, S. B., Schalper, K. A., Gettinger, S. N., Mahajan, A., Herbst, R. S., Chiang, A. C., ... & Kluger, H. M. (2020). Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology, 21(5), 655-663.
  • Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C. H., Han, J. Y., Lee, J. S., ... & Popat, S. (2018). Brigatinib versus crizotinib in ALK-positive non–small-cell lung cancer. New England Journal of Medicine, 379(21), 2027-2039.

Related Topics

Miami Cancer Institute Online Series (Multiple Modules)
This online educational series features Miami Cancer Institute (MCI) physician experts and national subject matter experts who have presented at our recent symposiums. Topics highlight the latest advances in cancer imaging, chemotherapy, surgical interventions, radiotherapy and proton therapy. Visit us often, as this catalog will be updated frequently.
Course Summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 General certificate of attendance
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
Course opens: 
10/01/2021
Course expires: 
01/31/2024
Part of: 
Miami Cancer Institute & Miami Neuroscience Institute: Miami Radiosurgery e-Learning Series

Manmeet Ahluwalia, M.D., MBA
Chief of Medical Oncology
Chief Scientific Officer and Deputy Director
Miami Cancer Institute
Baptist Health South Florida

Manmeet Ahluwalia, M.D., MBA, faculty for this educational event, is a researcher with Roswell Park Cancer Foundation, Velosano, Abbvie Inc., AstraZeneca, Bayer, BMS, Incyte, Merck, Mimivax, Novartis, Novcure Inc., and Pharmacyclics. Dr. Ahluwalia is a consultant with Xoft, Bayer, Celularity, GSK, Insightec, Kiyatec, Novocure, Apollomics, Janssen, Nuvation, Prelude, SDP Oncology and MedInnovate LLC, and a stockholder of Cytodyn, Doctible and Mimivax. He receives honorariums from Elsevier, Wiley and Xoft. He has indicated that the presentation or discussion will not include off-label or unapproved product usage. 

Michael McDermott, M.D., conference director for this educational activity, is a consultant with Deinde Medical and Stryker. 

Rupesh Kotecha, M.D., conference director for this educational activity, has received honorariums from Elekta AB, Accuray Inc., Viewray Inc., Novocure Inc., and Elsevier. He has received research support from Medtronic, Blue Earth Diagnostics, Novocure, Exelixis, GT Medical, AstraZeneca and Viewray. He is also on the speakers’ bureau for Novocure. 

All of the relevant financial relationships listed for these individuals have been mitigated.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.* 

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
              
Baptist Health South Florida designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 General certificate of attendance
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
Please login or register for a Baptist Health CME account to take this course.

Required Hardware/Software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome		Microsoft Edge
Microsoft Edge		Safari
Safari		Moxilla Firefox
Mozilla Firefox
Internet Explorer

Attention: Internet Explorer Users
This site offers limited support for Internet Explorer 11 (IE11). When using IE11, you will be prompted to download course videos instead of viewing them in the browser. After the course video downloads, the recordings will play.

Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.